Aspirin may reduce elevated risk of cancer caused by obesity
the ONA take:
Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome, according to a new study published online ahead of print in the Journal of Clinical Oncology has shown.
"This is important for people with Lynch Syndrome but affects the rest of us too. Lots of people struggle with their weight and this suggests the extra cancer risk can be cancelled by taking an aspirin," Professor Sir John Blum, professor of Clinical Genetics at Newcastle University in Leeds, UK, said.
For the study, researchers enrolled 937 patients with Lynch syndrome and randomly assigned them to receive aspirin 600 mg per day or placebo, plus resistant starch 30 g per day or placebo. Results showed that during a median follow-up of 55.7 months, the risk of colorectal cancer was nearly 2.5 times higher for overweight participants than for underweight and normal-weight participants.
Obese patients had a 1.77 times increased risk of Lynch syndrome-related cancer compared with normal-weight participants.
The findings suggest that overweight patients with Lynch syndrome are likely to benefit from obesity prevention and/or regular aspirin.
Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|